JAZZ News and Press, Jazz Pharmaceuticals plc From 03/08/23

Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes Canada NewsWire MISSISSAUGA, ON , ...

2023-03-07 09:35:38 ET Summary Avadel's narcolepsy treatment Lumryz has tentative FDA approval pending final approval, which is delayed due to a patent dispute that has since been resolved. Lumryz is a once-at-bedtime narcolepsy treatment using Avadel's drug-delivery tech, differe...

Summary Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a common movement disorder affecting 4% of adults > 40. Current treatments like be...

The US Drug Enforcement Agency has determined that MyMD Pharmaceuticals ( NASDAQ: MYMD ) experimental cannabinoid Supera-CBD is not a controlled substance. The candidate is under development for anxiety, pain, addiction, and seizures. Presently, with the exception of Jazz Pharmace...

Jazz Pharmaceuticals plc (JAZZ) Q4 2022 Earnings Conference Call March 01, 2023, 04:30 PM ET Company Participants Darren Fox - Executive Director of Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Dan Swisher - President and Chief Operating Offic...

While Jazz Pharmaceuticals ( NASDAQ: JAZZ ) missed on the top and bottom lines in its Q4 2022 results, its 2023 revenue outlook range included the consensus. The company is projecting 2023 total revenue of $3.675M to $3.875M (consensus $3.76B). Shares are up 5% in after-hours ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2022 Q4 earnings call. For further details see: Jazz Pharmaceuticals plc 2022 Q4 - Results - Earnings Call Presentation

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q4 Non-GAAP EPS of -$0.07 misses by $1.19 . Revenue of $972.12M (+8.4% Y/Y) misses by $3.75M . 2023 total revenue guidance of $3,675 to $3,875 million, 3% growth at the mid-point, vs. consensus of $3.76B. ...

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance PR Newswire Strong Execution Drove Record Revenues in 2022 of $3.7 billion , an increase of 18% over 2021 Positioned for Total Revenue and Net Inco...

Summary Jazz Pharmaceuticals, which is known for its Oxybate drug line used to treat narcolepsy, is seeking to diversify its product portfolio beyond Oxybate in anticipation of a revenue decline. After encouraging preliminary data for the treatment of first-line metastatic, HER2+ gastro...